SCHEMBL2880286

SCHEMBL2880286

Cc1ccccc1C1CCNCC1CNC(=O)O

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.44
HTR2C P28335 3/20 0.43
MAPT P10636 1/20 0.40
PKM P14618 1/20 0.40
SSTR1 P30872 4/20 0.39
SSTR4 P31391 4/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
SLC6A2 P23975 4/20 0.38
SLC6A4 P31645 4/20 0.38
BRD4 O60885 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2B P41595 1/20 0.38
SLC6A3 Q01959 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2880289 1.00 KDM1A (0.44) KDM1AHTR2CMAPTPKMSSTR1
SCHEMBL2882964 0.81 KDM1A (0.43) KDM1AHTR2CSSTR1SSTR4HTR2A
SCHEMBL2882967 0.81 KDM1A (0.43) KDM1AHTR2CSSTR1SSTR4HTR2A
SCHEMBL2882754 0.78 KDM1A (0.41) KDM1AHTR2CSSTR1SSTR4SLC6A2
SCHEMBL2882755 0.78 KDM1A (0.41) KDM1AHTR2CSSTR1SSTR4SLC6A2
SCHEMBL2883024 0.78 HTR2C (0.50) KDM1AHTR2CSSTR1SSTR4SLC6A2
SCHEMBL2883975 0.77 HTR2C (0.49) KDM1AHTR2CMAPTPKMSSTR1
SCHEMBL2878234 0.77 HTR2C (0.49) KDM1AHTR2CMAPTPKMSSTR1
SCHEMBL2878236 0.77 HTR2C (0.49) KDM1AHTR2CMAPTPKMSSTR1
SCHEMBL2877892 0.76 HTR2C (0.47) KDM1AHTR2CSLC6A2SLC6A4HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855294-B2 Cycloalkanopyridine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-21 US disclosed
US-20070191419-A1 Cycloalkanopyridine derivative MSD K.K. (JP) 2007-08-16 US disclosed
EP-1726590-A1 CYCLOALKANOPYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191419-A1 Cycloalkanopyridine derivative OPRL1, OPRK1, AVPR2 KDM1A 3484/4885HTR2C 699/4885MAPT 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.